A Suspected Association Between Sarcoidosis and Development of Diabetes Mellitus

Sponsor
University of Alabama at Birmingham (Other)
Overall Status
Withdrawn
CT.gov ID
NCT03805633
Collaborator
(none)
0
1
23.9
0

Study Details

Study Description

Brief Summary

The purpose of the study is to determine the characteristics of patients with diabetes and sarcoidosis and to compare them with those of patients with diabetes and no sarcoidosis. The investigators will approach these aims by measuring hemoglobin A1c, C peptide, insulin levels, and 2-hour glucose tolerance test results on the study population as well as collecting clinical data from records. Three groups of patients will be identified from pulmonary and endocrinology clinics at the University of Alabama at Birmingham. The first group will have a diagnosis of sarcoidosis without diabetes, the second group will have a diagnosis of both sarcoidosis and diabetes, and the third group will have a diagnosis of diabetes without sarcoidosis. Sample size is not pre-determined, but investigators anticipate this number to be less than 100. These patients will be asked in person during an office visit to join the study. For each patient who agrees to join, at a clinic visit, investigators will review and sign consent. Following the visit or at a time convenient for each patient, study subjects will undergo a fasting plasma venous sample collection for a hemoglobin A1c, C peptide, insulin level and perform a 2-hour oral glucose tolerance test. The degree of glucose intolerance and prevalence of diabetes will be analyzed and compared between the groups and to historical published control data via T test comparisons. At a later separate visit, patients recruited will undergo ultrasound of the pancreas to assess pancreatic size and morphology.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Venous blood sample
  • Diagnostic Test: Ultrasound of pancreas

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
0 participants
Observational Model:
Case-Control
Time Perspective:
Cross-Sectional
Official Title:
A Suspected Association Between Sarcoidosis and Development of Diabetes Mellitus
Actual Study Start Date :
Feb 2, 2018
Anticipated Primary Completion Date :
Jul 31, 2019
Anticipated Study Completion Date :
Jan 31, 2020

Arms and Interventions

Arm Intervention/Treatment
Sarcoidosis Patients

Patients referred to UAB Pulmonology who are diagnosed with sarcoidosis.

Diagnostic Test: Venous blood sample
Venous blood samples will be obtained for hemoglobin A1c, C peptide, insulin level, and 2-hour fasting glucose tolerance test.

Diagnostic Test: Ultrasound of pancreas
Ultrasound of pancreas will be obtained on all study participants.

Diabetes Patients

Patients followed by UAB Endocrinology with diabetes mellitus.

Diagnostic Test: Venous blood sample
Venous blood samples will be obtained for hemoglobin A1c, C peptide, insulin level, and 2-hour fasting glucose tolerance test.

Diagnostic Test: Ultrasound of pancreas
Ultrasound of pancreas will be obtained on all study participants.

Sarcoidosis and Diabetes patients

Patients followed by UAB Pulmonary and/or UAB Endocrinology with both sarcoidosis and diabetes mellitus.

Diagnostic Test: Venous blood sample
Venous blood samples will be obtained for hemoglobin A1c, C peptide, insulin level, and 2-hour fasting glucose tolerance test.

Diagnostic Test: Ultrasound of pancreas
Ultrasound of pancreas will be obtained on all study participants.

Outcome Measures

Primary Outcome Measures

  1. Change in glucose during oral glucose tolerance test (oGTT) [Baseline]

Secondary Outcome Measures

  1. Change in C peptide over oGTT [Baseline]

  2. Change in insulin response oGTT [Baseline]

  3. Hemoglobin A1c (HbA1c) [Baseline]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Any adult patient referred to or followed in UAB pulmonary clinic with an established diagnosis of sarcoidosis. Any adult patient followed in UAB endocrinology clinic with a diagnosis of diabetes mellitus (excluding type 1 diabetes).
Exclusion Criteria:
  • Type 1 diabetes and/or chronic use of corticosteroids.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Alabama at Birmingham Birmingham Alabama United States 35233

Sponsors and Collaborators

  • University of Alabama at Birmingham

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Fernando Ovalle, Medical Doctor, Professor, University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT03805633
Other Study ID Numbers:
  • IRB-300000289
First Posted:
Jan 16, 2019
Last Update Posted:
Dec 13, 2019
Last Verified:
Dec 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 13, 2019